Although p53 has not been included in international guidelines for the time being for the reasons mentioned above, there is a large consensus that studies on the efficacy of neoadjuvant chemotherapy (NAC) in BC have shown significantly higher pathological complete response (pCR) rates in tumors with p53 mutations compared to wild-type tumors [6]. The gene discussed is TP53; the disease is breast cancer.